We sit down with DHL Supply Chain EMEA CEO Hendrik Venter and Managing Director for Türkiye, Buket Cox, to learn why DHL are ...

DHL Group plans to spend ... $5 billion in global revenue in 2024. Investment in the health care sector — including medical device, clinical trial, biopharma, cell and gene therapy logistics ...

Shipping and logistics giant DHL Group is earmarking 2 billion ... in order to meet growing demand from the biopharma industry. Half of the investment will target the Americas with the remaining ...

DHL Group has announced an investment of €2 billion over the next five years to enhance its logistics capabilities in the life sciences and healthcare sector.

The company, which trades as DHL ... The investment will cater to growing customer demand in pharmaceuticals, medical devices and fast-growing areas like clinical trials, biopharma, and cell ...

The investment is part of DHL’s recent strategy to double health ... a specialty courier that provides logistics services for clinical trials, biopharma, and cell and gene therapies, for $ ...

DHL Group has announced a strategic investment of EUR 2 billion over the next five years to enhance its logistics ...

The new hub is part of the company’s $568m investment in Asia Pacific for the life sciences and healthcare sector.

where to put inventory to best position themselves." He also talks about DHL's investments in Southeast Asia and expansion in healthcare logistics.